In a nutshell This study investigated the use of MRI predictive results to decide the best treatment for patients with locally advanced rectal cancer (LARC). Researchers suggested that early MRI results should be used in the treatment decision making. Some background Colorectal cancer is the third most common cancer in the world. Patients with LARC...
Read More
In a nutshell This trial is examining if adding antibody drug rituximab (Rituxan) and enzyme drug hyaluronidase human (Hycela) can increase the effectiveness of the standard treatment for melanoma. The main outcomes of this trial will be to examine the side effects experienced by patients and tumor response. This study is recruiting in...
Read More
In a nutshell This phase 1/2 trial is examining the best dose and side effects of a combined treatment with encorafenib (Braftovi), cetuximab (Erbitux) and nivolumab (Opdivo). The main outcome to be measured will be the tumor response to the treatment. This trial is being conducted in Texas, US. The details Colorectal cancer is one of the leading...
Read More
In a nutshell This study investigated the best interval time between chemoradiation therapy and rectal cancer surgery for the best outcomes in patients with rectal cancer. Researchers suggested that waiting at least 8 weeks until the surgery increases the tumor response to the treatment. Some background The standard treatment for locally advanced...
Read More
In a nutshell This trial is examining the effectiveness and toxicity of COTI-2 treatment in patients with advanced cancer. The main outcomes to be measured will be cancer response to the treatment and number of side effects. This study is being conducted in Texas, US. The details Cancer resistance to therapy affects successful cancer treatment. The...
Read More
In a nutshell This study investigated if durvalumab (Infinzi) is effective in advanced non-small cell lung cancer (NSCLC) that has progressed on previous therapies. They found that the response to durvalumab was greatest in patients with high PD-L1 expression. Some background Non-small cell lung cancer (NSCLC) is the most common form...
Read More
In a nutshell This study wanted to find out which treatment was better before surgery for patients with HER2-positive breast cancer, trastuzumab emtansine (Kadcycla) plus pertuzumab (Perjeta), or a standard treatment. The study found that patients treated with trastuzumab emtansine plus pertuzumab (TEP) were more likely to have cancer...
Read More
In a nutshell This phase 2 trial is examining the effectiveness of FOLFOX chemotherapy to treat patients with rectal cancer, without surgery and radiation. The main outcome to be measured will be the tumor response to the treatment. This study is being conducted in New York, US. The details This year an estimated 44,180 people will be diagnosed with...
Read More
In a nutshell This study investigated if postoperative radiotherapy (PORT) is effective in non-small cell lung cancer (NSCLC) after pneumonectomy (PMT; lung surgery). They found that PORT improved survival and was well tolerated in these patients. Some background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer....
Read More
In a nutshell This study examined the long-term outcomes of patients with melanoma who received surgery and high-dose interferon-α (HDI). This study found that HDI treatment resulted in a decreased chance of the cancer coming back after 17 years. Some background Surgery followed by anti-cancer therapy has remained the standard of care...
Read More
In a nutshell This study evaluated the effectiveness of osimertinib (Tagrisso) in patients over age 80 with advanced small cell lung cancer (NSCLC). This study found that these elderly patients had similar outcomes to patients in clinical trials. Some background NSCLC is the most common type of lung cancer. One common treatment is...
Read More
In a nutshell This study evaluated the quality of life for survivors of melanoma who received immunotherapy. This study found that melanoma survivors had a significantly lower quality of life compared to the general population. Some background Immune checkpoint inhibitors are a new class of anti-cancer drugs that take advantage of the...
Read More
